Post-treatment surveillance in a large cohort of patients with colon cancer

American Journal of Managed Care

Volumn 17, Issue 5, 2011, Pages 329-336

  Hu, Chung Yuan ^a   Delclos, George L ^a   Chan, Wenyaw ^a   Du, Xianglin L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; COLON ADENOCARCINOMA; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ADENOCARCINOMA; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; COLONOSCOPY; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; GUIDELINES AS TOPIC; HUMANS; LOGISTIC MODELS; MALE; MEDICARE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OFFICE VISITS; PATIENT COMPLIANCE; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVORS; UNITED STATES;

EID: 79960278404     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Horner MJ, Ries LAG, Krapcho M, et al. SEER cancer statistics review, 1975-2006. Based on November 2008 SEER data submission; posted to the SEER Web site 2009. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/ 1975-2006/. Accessed April 16, 2001.
2. Devesa JM, Morales V, Enriquez JM, et al. Colorectal cancer: the bases for a comprehensive follow-up. Dis Colon Rectum. 1988;31(8):636-652.
3. Abulafi AM, Williams NS. Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg. 1994;81(1):7-19. (Pubitemid 24048923)
4. Manfredi S, Benhamiche AM, Meny B, Cheynel N, Rat P, Faivre J. Population-based study of factors influencing occurrence and prognosis of local recurrence after surgery for rectal cancer. Br J Surg. 2001;88(9):1221-1227. (Pubitemid 34015607)
5. Galandiuk S, Wieand HS, Moertel CG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet. 1992;174(1):27-32.
6. Engstrom PF, Arnoletti JP, Benson AB III, et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines). http://www.nccn.org/professionals/ physician-gls/PDF/colon.pdf. Accessed April 27, 2010.
7. Figueredo A, Rumble RB, Maroun J, et al; Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:e26.
8. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324(7341):e813.
9. Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer (update in Cochrane Database Syst Rev. 2007;(1):CD002200). Cochrane Database Syst Rev. 2002;(1):CD002200.
10. Surveillance, Epidemiology, and End Results (SEER) Program. Limited-use data (1973-2006). Bethesda, MD: Cancer Statistics Branch, Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute. Released April 2009; based on the November 2007 submission. http://seer.cancer.gov/. Accessed April 16, 2011.
11. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31(8):732-748.
12. Du XL, Fang S, Vernon SW, et al. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer. 2007;110(3):660-669. (Pubitemid 47106157)
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
14. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075-1079, 1081-1090.
15. National Cancer Institute. SEER-Medicare: calculation of comorbidity weights. http://healthservices.cancer.gov/seermedicare/program/comorbidity.html. Accessed December 4, 2009.
16. Desch CE, Benson AB III, Smith TJ, et al. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol. 1999;17(4):e1312.
17. Cooper GS, Yuan Z, Chak A, Rimm AA. Geographic and patient variation among Medicare beneficiaries in the use of follow-up testing after surgery for nonmetastatic colorectal carcinoma. Cancer. 1999;85(10):2124-2131. (Pubitemid 29215550)
18. Gross CP, Andersen MS, Krumholz HM, McAvay GJ, Proctor D, Tinetti ME. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA. 2006;296(23):2815-2822. (Pubitemid 44969181)
19. Cooper GS, Payes JD. Receipt of colorectal testing prior to colorectal carcinoma diagnosis. Cancer. 2005;103(4):696-701. (Pubitemid 40216396)
20. Ko CW, Kreuter W, Baldwin LM. Effect of Medicare coverage on use of invasive colorectal cancer screening tests. Arch Intern Med. 2002;162:2581-2586. (Pubitemid 35453497)
21. Benson AB III, Desch CE, Flynn PJ, et al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol. 2000;18(22):3586-3588.
22. Desch CE, Benson AB III, Somerfield MR, et al; American Society of Clinical Oncology. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline [published correction appears in J Clin Oncol. 2006;24(7):1224]. J Clin Oncol. 2005;23(33):8512-8519.
23. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352-358. (Pubitemid 20042739)
24. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93(11):850-857. (Pubitemid 32590779)
25. Cooper GS, Kou TD, Reynolds HL Jr. Receipt of guideline-recommended follow-up in older colorectal cancer survivors: a population-based analysis. Cancer. 2008;113(8):2029-2037.
26. McCall JL, Black RB, Rich CA, et al. The value of serum carcino-embryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum. 1994;37(9):875-881. (Pubitemid 24281920)
27. Wanebo HJ, Llaneras M, Martin T, Kaiser D. Prospective monitoring trial for carcinoma of colon and rectum after surgical resection. Surg Gynecol Obstet. 1989;169(6):479-487. (Pubitemid 20026308)
28. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270(8):943-947. (Pubitemid 23244732)
29. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol. 2009;18(1):15-24.
30. Cooper GS, Schultz L, Simpkins J, Lafata JE. The utility of administrative data for measuring adherence to cancer surveillance care guidelines. Med Care. 2007;45(1):66-72.